NCT04702568 - A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions

Paroxysmal Nocturnal HemoglobinuriaPNH

Interventions

DRUG

BCX9930

BCX9930 for oral administration

DRUG

Eculizumab

Administered at stable dose at the time of study entry

DRUG

Ravulizumab

Administered at stable dose at the time of study entry

Trial Locations (5)

Study Center, Vienna

Study Center, Bloemfontein

Study Center, Cape Town

Study Center, Pretoria

Study Center, London